21-hydroxylase deficiency primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
Prenatal diagnosis of 21-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment. | Prenatal diagnosis of 21-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment. | ||
==Primary prevention== | ==Primary prevention== | ||
Prenatal diagnosis of 21-hydroxylase deficiency in those patients with positive family history, is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment. The available tests are: [[Amniotic fluid]] testing and oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus biopsies. Utilize fetal DNA extracted from maternal blood through noninvasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref> | * Prenatal diagnosis of 21-hydroxylase deficiency in those patients with positive family history, is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment. | ||
* The available tests are: [[Amniotic fluid]] testing and oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus biopsies. Utilize fetal DNA extracted from maternal blood through noninvasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:16, 21 July 2017
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency primary prevention On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency primary prevention |
|
Risk calculators and risk factors for 21-hydroxylase deficiency primary prevention |
Overview
Prenatal diagnosis of 21-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment.
Primary prevention
- Prenatal diagnosis of 21-hydroxylase deficiency in those patients with positive family history, is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment.
- The available tests are: Amniotic fluid testing and oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus biopsies. Utilize fetal DNA extracted from maternal blood through noninvasive methods.[1]
References
- ↑ Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.